Morgan Stanley analyst Michael Ulz raised the firm’s price target on Dyne Therapeutics to $52 from $48 and keeps an Overweight rating on the shares. Dyne highlighted promising, de-risking Phase 1/2 updates for both DYNE-101 and DYNE-251, while progress across both programs continues and importantly management remains engaged with regulators on determining an expedited approval path with clarity expected by year-end, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $53 from $43 at Piper Sandler
- Dyne Therapeutics price target raised to $55 from $48 at H.C. Wainwright
- Dyne Therapeutics price target raised to $50 from $42 at Chardan
- Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics reports Q2 EPS (70c), consensus (72c)